A Study of KC1036 in Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2023-07-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety，tolerability, pharmacokinetics, and
preliminary efficacy of KC1036 in participants with advanced recurrent or metastatic solid
tumors. The trial will be divided into three parts: dose-escalation phase, dose-expansion
phase, RP2D-extension phase.